fda tirzepatide update today approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA Clarifies Compounding Rules as

The consultant I spoke with works in both the private and public sectors

These agents provide multiple benefits, including weight reduction, cardio-renal protection, improved heart failure symptoms and hepatic steatohepatitis, and overall reduced mortality [2,3,4,5,6,7,8,9]

Navigating the WADA Prohibited List: Where Things Get Murky Alright, let's get into the weeds

I personally take this one

These drugs are particularly valuable for patients with obesity-related conditions like metabolic syndrome, prediabetes, or as recently approved, obstructive sleep apnea (OSA) the FDA approved tirzepatide in OSA because weight loss led to significant improvement in apnea-hypopnea index and symptom resolutionfda.govfda.gov